DIAGNOSTIC TEST OF MOLECULAR RAPID TEST AGAINST REAL-TIME PCR ON DETECTING BCR-ABL CHRONIC MYELOID LEUKEMIA
DOI:
https://doi.org/10.34011/juriskesbdg.v17i2.2865Keywords:
chronic myeloid leukemia, TCM BCR-ABL, real time PCR BCR-ABL, uji diagnostikAbstract
Chronic Myeloid Leukemia (CML) merupakan suatu kondisi yang ditandai oleh proliferasi abnormal sel hematopoietik yang dapat terjadi pada berbagai kelompok usia. Deteksi Breakpoint Cluster Region-Abelson (BCR-ABL) penting untuk mengidentifikasi keberadaan Kromosom Philadelphia (Ph 1 chr). Pemeriksaan Real-Time Polymerase Chain Reaction (Real-Time PCR) merupakan gold standar untuk deteksi BCR-ABL, namun memiliki keterbatasan seperti waktu pengerjaan lama dan biaya tinggi. Tes Cepat Molekuler (TCM) melalui platform GenXpert menawarkan alternatif yang lebih cepat dan praktis. Penelitian ini bertujuan mengevaluasi kinerja TCM BCR-ABL dibandingkan Real-Time PCR. Desain penelitian menggunakan pendekatan cross sectional dengan 54 sampel yang diperoleh melalui teknik consecutive sampling berdasarkan rumus Lemeshow. Hasil penelitian menunjukkan sensitivitas 91%, spesifisitas 90%, positive predictive value (PPV) 94%, dan negative predictive value (NPV) 86%. Uji Wilcoxon menunjukkan tidak ada perbedaan signifikan antara kedua metode (p=0,100). Berdasarkan hasil penelitian tersebut, TCM memiliki kinerja diagnostik yang mendekati Real-Time PCR dan berpotensi digunakan sebagai alternatif pemeriksaan cepat dan efisien pada deteksi CML.
Downloads
References
Suttorp M, Millot F, Sembill S, Deutsch H, Metzler M. Definition, epidemiology, pathophysiology, and essential criteria for diagnosis of pediatric chronic myeloid leukemia. Cancers (Basel). 2021;13(4):1-21. doi:10.3390/cancers13040798
El-Tanani M, Nsairat H, Matalka II, et al. The impact of the BCR-ABL oncogene in the pathology and treatment of chronic myeloid leukemia. Pathol Res Pract. 2024;254. doi:10.1016/j.prp.2024.155161
Sung H, Ferlay J, Siegel RL, et al. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin. 2021;71(3):209-249. doi:10.3322/caac.21660
Bray F, Laversanne M, Sung H, et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2024;74(3):229-263. doi:10.3322/caac.21834
Smitalova D, Dvorakova D, Racil Z, Romzova M. Digital PCR can provide improved BCR-ABL1 detection in chronic myeloid leukemia patients in deep molecular response and sensitivity of standard quantitative methods using EAC assays. Pract Lab Med. 2021;25(January 2020):e00210. doi:10.1016/j.plabm.2021.e00210
Budiarto E. Metodologi Penelitian Kedokteran : Sebuah Pengantar. EGC; 2004.
Tumbelaka A. Telaah Kritis Makalah Uji Diagnostik. Sari Pediatr. 2016;4:98. doi:10.14238/sp4.2.2002.98-102
Azis SI, Tandarto M, Adilah I, et al. Nilai sensitivitas, spesifisitas, nilai duga positif (NDP) dan nilai duga negatif (NDN) tes diagnostik cepat antigen pada skrining pasien Corona Virus Disease-19 (COVID-19) di Poliklinik Fakultas Kedokteran Universitas Mulawarman, Samarinda. J Ked Mulawarman. 2022;9(1):14-23.
Permana GP, Rahayu IG, Kurniawan E, Rohayati. Analisis Unit Cost Pemeriksaan Breakpoint Cluster Region - Abelson (BCR-ABL) Dalam Peningkatan Pendapatan Rsup Dr. Hasan Sadikin Bandung. J Med Lab Sci. 2024;4(2). doi:10.36086/medlabscience.v4i2
Swift A, Heale R, Twycross A. What are sensitivity and specificity? Evid Based Nurs. 2020;23(1):2-5. doi:10.1136/ebnurs-2019-103225
Thermo Fisher Scientific. PCR Basic. Thermo Fisher Scientific Inc. 2016. https://www.thermofisher.com/id/en/home/life-science/cloning/cloning-learning-center/invitrogen-school-of-molecular-biology/pcr-education/pcr-reagents-enzymes/pcr-basics.html
Cepheid. Xpert ® BCR-ABL Ultra.; 2022. https://infomine.cepheid.com/sites/default/files/2023-04/Xpert BCR-ABL Ultra Assay-INDONESIAN Package Insert 302-0742-ID Rev. D.pdf
Aliviameita A; P. Buku Ajar Mata Kuliah Hematologi. Cetakan pe. (Sartika, Septi B; Multazam M., ed.). UMSIDA Press; 2019.
Press RD, Kamel-Reid S, Ang D. BCR-ABL1 RT-qPCR for monitoring the molecular response to tyrosine kinase inhibitors in chronic myeloid leukemia. J Mol Diagnostics. 2013;15(5):565-576. doi:10.1016/j.jmoldx.2013.04.007
Brown JT, Beldorth IJ, Laosinchai-Wolf W, et al. Analytical Validation of a Highly Sensitive, Multiplexed Chronic Myeloid Leukemia Monitoring System Targeting BCR-ABL1 RNA. J Mol Diagnostics. 2019;21(4):718-733. doi:10.1016/j.jmoldx.2019.03.002
Jobbagy Z, van Atta R, Murphy KM, Eshleman JR, Gocke CD. Evaluation of the Cepheid GeneXpert BCR-ABL assay. J Mol Diagnostics. 2007;9(2):220-227. doi:10.2353/jmoldx.2007.060112
More S, Chatterjee T, Agarwal C, Pujani M, Chandoke RK. Fully Automated GeneXpert BCR-ABL1 Assay versus Standard Nonautomated BCR-ABL1 Real-Time Reverse Transcription – Polymerase Chain Reaction Quantitation : A Study from Tertiary Care Institute in India. Published online 2024:1-5. doi:10.4103/jmau.jmau
Arora R, Press RD. Measurement of BCR-ABL1 transcripts on the International Scale in the United States: current status and best practices. Leuk Lymphoma. 2017;58(1):8-16. doi:10.1080/10428194.2016.1190974
Siswosudarmo R. Tes Diagnostik. J Metodol Penelit. 2017;12.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2025 JURNAL RISET KESEHATAN POLTEKKES DEPKES BANDUNG
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
